Alpha Cognition Inc
ACOG
Classifica tra le azioni
#20051
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Prezzo delle azioni
$8.63
Capitalizzazione di mercato
$134.04M
Variazione (1 giorno)
0.23%
Variazione (1 anno)
71.57%
Paese
US
Scambia Alpha Cognition Inc (ACOG)
Categoria
Healthcare
Storico del prezzo dell'azione per Alpha Cognition Inc (ACOG)
Prezzo di chiusura più alto: $5.46 il 2024-12-01
Prezzo di chiusura più basso: $18.75 il 2021-06-01
Prezzo di chiusura più basso: $18.75 il 2021-06-01
Storico del prezzo dell'azione di Alpha Cognition Inc dal 2021 al 2026
Andamento annuale del prezzo dell'azione
| Anno | Performance |
|---|---|
| 2024 | -51.49% |
| 2023 | 87.35% |
| 2022 | -73.46% |
| 2021 | 0.00% |
Prezzo dell'azione per aziende simili o concorrenti
| Azienda | Prezzo dell'azione | Variazione 1a% | Il paese |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
